APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Selected research

Market Structure

Global Circulating Tumor Cells Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173893750321 December 2025197 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cells Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cells Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cells Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cells Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cells Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.

Report Includes

Read the full market overview

This report provides an overview of the global Circulating Tumor Cells market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Circulating Tumor Cells and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Circulating Tumor Cells revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Circulating Tumor Cells market size, projected growth trends, production technologies, key applications, and end-use industries.

Circulating Tumor Cells Segment by Company

Menarini-Silicon Biosystems

Qiagen (Adnagen)

Advanced Cell Diagnostics

ApoCell

Epic Sciences

Greiner Bio-one GmbH

Cynvenio

SurExamBio-Tech

Fluxion Biosciences

Ikonisys

Hangzhou Watson Biotech

Biocept

CytoTrack

Guangzhou Wondfo Biotech

Celsee

Clearbridge Biomedics

ANGLE plc

Circulating Tumor Cells Segment by Type

CTC Enrichment

CTC Detection

CTC Analysis

Circulating Tumor Cells Segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

Circulating Tumor Cells Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Circulating Tumor Cells in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Circulating Tumor Cells industry.

Chapter 3: Detailed analysis of Circulating Tumor Cells companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cellsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Circulating Tumor Cells Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of CTC Enrichment Table 3. Key Players of CTC Detection Table 4. Key Players of CTC Analysis Table 4. Global Circulating Tumor Cells Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Breast Cancer Table 6. Key Players of Prostate Cancer Table 7. Key Players of Colorectal Cancer Table 8. Key Players of Lung Cancer Table 9. Key Players of Others Table 10. Global Circulating Tumor Cells Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global Circulating Tumor Cells Market Size by Region (2021-2026) & (US$ Million) Table 12. Global Circulating Tumor Cells Market Share by Region (2021-2026) Table 13. Global Circulating Tumor Cells Market Size by Region (2027-2032) & (US$ Million) Table 14. Global Circulating Tumor Cells Market Share by Region (2027-2032) Table 15. Circulating Tumor Cells Industry Trends Table 16. Circulating Tumor Cells Industry Drivers Table 17. Circulating Tumor Cells Industry Opportunities and Challenges Table 18. Circulating Tumor Cells Industry Restraints Table 19. Global Circulating Tumor Cells Revenue by Company (US$ Million) & (2021-2026) Table 20. Global Circulating Tumor Cells Revenue Market Share by Company (2021-2026) Table 21. Global Circulating Tumor Cells Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global Circulating Tumor Cells Key Company Head Office and Area Served Table 23. Global Circulating Tumor Cells Company, Product Type & Application Table 24. Global Circulating Tumor Cells Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global Circulating Tumor Cells by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global Circulating Tumor Cells Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 29. Global Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 30. Global Circulating Tumor Cells Revenue Market Share by Type (2021-2026) Table 31. Global Circulating Tumor Cells Revenue Market Share by Type (2027-2032) Table 32. Global Circulating Tumor Cells Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 34. Global Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 35. Global Circulating Tumor Cells Revenue Market Share by Application (2021-2026) Table 36. Global Circulating Tumor Cells Revenue Market Share by Application (2027-2032) Table 37. Menarini-Silicon Biosystems Company Information Table 38. Menarini-Silicon Biosystems Business Overview Table 39. Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio Table 41. Menarini-Silicon Biosystems Recent Development Table 42. Qiagen (Adnagen) Company Information Table 43. Qiagen (Adnagen) Business Overview Table 44. Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio Table 46. Qiagen (Adnagen) Recent Development Table 47. Advanced Cell Diagnostics Company Information Table 48. Advanced Cell Diagnostics Business Overview Table 49. Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio Table 51. Advanced Cell Diagnostics Recent Development Table 52. ApoCell Company Information Table 53. ApoCell Business Overview Table 54. ApoCell Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. ApoCell Circulating Tumor Cells Product Portfolio Table 56. ApoCell Recent Development Table 57. Epic Sciences Company Information Table 58. Epic Sciences Business Overview Table 59. Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Epic Sciences Circulating Tumor Cells Product Portfolio Table 61. Epic Sciences Recent Development Table 62. Greiner Bio-one GmbH Company Information Table 63. Greiner Bio-one GmbH Business Overview Table 64. Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio Table 66. Greiner Bio-one GmbH Recent Development Table 67. Cynvenio Company Information Table 68. Cynvenio Business Overview Table 69. Cynvenio Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Cynvenio Circulating Tumor Cells Product Portfolio Table 71. Cynvenio Recent Development Table 72. SurExamBio-Tech Company Information Table 73. SurExamBio-Tech Business Overview Table 74. SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. SurExamBio-Tech Circulating Tumor Cells Product Portfolio Table 76. SurExamBio-Tech Recent Development Table 77. Fluxion Biosciences Company Information Table 78. Fluxion Biosciences Business Overview Table 79. Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Fluxion Biosciences Circulating Tumor Cells Product Portfolio Table 81. Fluxion Biosciences Recent Development Table 82. Ikonisys Company Information Table 83. Ikonisys Business Overview Table 84. Ikonisys Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Ikonisys Circulating Tumor Cells Product Portfolio Table 86. Ikonisys Recent Development Table 87. Hangzhou Watson Biotech Company Information Table 88. Hangzhou Watson Biotech Business Overview Table 89. Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio Table 91. Hangzhou Watson Biotech Recent Development Table 92. Biocept Company Information Table 93. Biocept Business Overview Table 94. Biocept Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Biocept Circulating Tumor Cells Product Portfolio Table 96. Biocept Recent Development Table 97. CytoTrack Company Information Table 98. CytoTrack Business Overview Table 99. CytoTrack Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. CytoTrack Circulating Tumor Cells Product Portfolio Table 101. CytoTrack Recent Development Table 102. Guangzhou Wondfo Biotech Company Information Table 103. Guangzhou Wondfo Biotech Business Overview Table 104. Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio Table 106. Guangzhou Wondfo Biotech Recent Development Table 107. Celsee Company Information Table 108. Celsee Business Overview Table 109. Celsee Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Celsee Circulating Tumor Cells Product Portfolio Table 111. Celsee Recent Development Table 112. Clearbridge Biomedics Company Information Table 113. Clearbridge Biomedics Business Overview Table 114. Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. Clearbridge Biomedics Circulating Tumor Cells Product Portfolio Table 116. Clearbridge Biomedics Recent Development Table 117. ANGLE plc Company Information Table 118. ANGLE plc Business Overview Table 119. ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 120. ANGLE plc Circulating Tumor Cells Product Portfolio Table 121. ANGLE plc Recent Development Table 122. North America Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 123. North America Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 124. North America Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 125. North America Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 126. North America Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. North America Circulating Tumor Cells Market Size by Country (2021-2026) Table 128. North America Circulating Tumor Cells Market Size by Country (2027-2032) Table 129. Europe Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 130. Europe Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 131. Europe Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 132. Europe Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 133. Europe Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Europe Circulating Tumor Cells Market Size by Country (2021-2026) Table 135. Europe Circulating Tumor Cells Market Size by Country (2027-2032) Table 136. China Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 137. China Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 138. China Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 139. China Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 140. Asia Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 141. Asia Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 142. Asia Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 143. Asia Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 144. Asia Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia Circulating Tumor Cells Market Size by Country (2021-2026) Table 146. Asia Circulating Tumor Cells Market Size by Country (2027-2032) Table 147. South America, Middle East & Africa Circulating Tumor Cells Market Size by Type (2021-2026) & (US$ Million) Table 148. South America, Middle East & Africa Circulating Tumor Cells Market Size by Type (2027-2032) & (US$ Million) Table 149. South America, Middle East & Africa Circulating Tumor Cells Market Size by Application (2021-2026) & (US$ Million) Table 150. South America, Middle East & Africa Circulating Tumor Cells Market Size by Application (2027-2032) & (US$ Million) Table 151. South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2021-2026) Table 153. South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2027-2032) Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Circulating Tumor Cells Product Image Figure 2. Global Circulating Tumor Cells Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Circulating Tumor Cells Market Share by Type: 2025 VS 2032 Figure 4. CTC Enrichment Image Figure 5. CTC Detection Image Figure 6. CTC Analysis Image Figure 7. Global Circulating Tumor Cells Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 8. Global Circulating Tumor Cells Market Share by Application: 2025 VS 2032 Figure 9. Breast Cancer Image Figure 10. Prostate Cancer Image Figure 11. Colorectal Cancer Image Figure 12. Lung Cancer Image Figure 13. Others Image Figure 14. Global Circulating Tumor Cells Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 16. Global Circulating Tumor Cells Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Circulating Tumor Cells Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Circulating Tumor Cells Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Circulating Tumor Cells Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Circulating Tumor Cells Revenue Market Share by Type (2021-2032) Figure 23. Global Circulating Tumor Cells Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Circulating Tumor Cells Revenue Market Share by Application (2021-2032) Figure 25. North America Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 26. North America Circulating Tumor Cells Market Share by Type (2021-2032) Figure 27. North America Circulating Tumor Cells Market Share by Application (2021-2032) Figure 28. North America Circulating Tumor Cells Market Share by Country (2021-2032) Figure 29. United States Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 30. Canada Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 32. Europe Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 33. Europe Circulating Tumor Cells Market Share by Type (2021-2032) Figure 34. Europe Circulating Tumor Cells Market Share by Application (2021-2032) Figure 35. Europe Circulating Tumor Cells Market Share by Country (2021-2032) Figure 36. Germany Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 37. France Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 39. Italy Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 40. Russia Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 42. China Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 43. China Circulating Tumor Cells Market Share by Type (2021-2032) Figure 44. China Circulating Tumor Cells Market Share by Application (2021-2032) Figure 45. Asia Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 46. Asia Circulating Tumor Cells Market Share by Type (2021-2032) Figure 47. Asia Circulating Tumor Cells Market Share by Application (2021-2032) Figure 48. Asia Circulating Tumor Cells Market Share by Country (2021-2032) Figure 49. Japan Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 53. India Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 54. Australia Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Circulating Tumor Cells Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Circulating Tumor Cells Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Circulating Tumor Cells Market Share by Country (2021-2032) Figure 59. Brazil Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 64. UAE Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 66. Chile Circulating Tumor Cells Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
Applications
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
Companies covered
  • Menarini-Silicon Biosystems
  • Qiagen (Adnagen)
  • Advanced Cell Diagnostics
  • ApoCell
  • Epic Sciences
  • Greiner Bio-one GmbH
  • Cynvenio
  • SurExamBio-Tech
  • Fluxion Biosciences
  • Ikonisys
  • Hangzhou Watson Biotech
  • Biocept
  • CytoTrack
  • Guangzhou Wondfo Biotech
  • Celsee
  • Clearbridge Biomedics
  • ANGLE plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Circulating Tumor Cells Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 CTC Enrichment
  5. 1.2.3 CTC Detection
  6. 1.2.4 CTC Analysis
  7. 1.3 Market Analysis by Application
  8. 1.3.1 Global Circulating Tumor Cells Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  9. 1.3.2 Breast Cancer
  10. 1.3.3 Prostate Cancer
  11. 1.3.4 Colorectal Cancer
  12. 1.3.5 Lung Cancer
  13. 1.3.6 Others
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Circulating Tumor Cells Growth Trends by Region
  16. 1.5.1 Global Circulating Tumor Cells Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Circulating Tumor Cells Market Size by Region (2021-2026)
  18. 1.5.3 Circulating Tumor Cells Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Circulating Tumor Cells Market Dynamics
  1. 2.1 Circulating Tumor Cells Industry Trends
  2. 2.2 Circulating Tumor Cells Industry Drivers
  3. 2.3 Circulating Tumor Cells Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cells Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Circulating Tumor Cells Revenue by Company (2021-2026)
  2. 3.2 Global Circulating Tumor Cells Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Circulating Tumor Cells Key Company Head office and Area Served
  4. 3.4 Global Circulating Tumor Cells Company, Product Type & Application
  5. 3.5 Global Circulating Tumor Cells Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Circulating Tumor Cells Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Circulating Tumor Cells Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Circulating Tumor Cells Tier 1, Tier 2, and Tier 3
4 Circulating Tumor Cells Market by Type
  1. 4.1 Global Circulating Tumor Cells Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Circulating Tumor Cells Market Size by Type (2021-2032)
  3. 4.3 Global Circulating Tumor Cells Market Size Share by Type (2021-2032)
5 Circulating Tumor Cells Market by Application
  1. 5.1 Global Circulating Tumor Cells Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Circulating Tumor Cells Market Size by Application (2021-2032)
  3. 5.3 Global Circulating Tumor Cells Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Menarini-Silicon Biosystems
  2. 6.1.1 Menarini-Silicon Biosystems Company Information
  3. 6.1.2 Menarini-Silicon Biosystems Business Overview
  4. 6.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio
  6. 6.1.5 Menarini-Silicon Biosystems Recent Developments
  7. 6.2 Qiagen (Adnagen)
  8. 6.2.1 Qiagen (Adnagen) Company Information
  9. 6.2.2 Qiagen (Adnagen) Business Overview
  10. 6.2.3 Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio
  12. 6.2.5 Qiagen (Adnagen) Recent Developments
  13. 6.3 Advanced Cell Diagnostics
  14. 6.3.1 Advanced Cell Diagnostics Company Information
  15. 6.3.2 Advanced Cell Diagnostics Business Overview
  16. 6.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio
  18. 6.3.5 Advanced Cell Diagnostics Recent Developments
  19. 6.4 ApoCell
  20. 6.4.1 ApoCell Company Information
  21. 6.4.2 ApoCell Business Overview
  22. 6.4.3 ApoCell Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 ApoCell Circulating Tumor Cells Product Portfolio
  24. 6.4.5 ApoCell Recent Developments
  25. 6.5 Epic Sciences
  26. 6.5.1 Epic Sciences Company Information
  27. 6.5.2 Epic Sciences Business Overview
  28. 6.5.3 Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Epic Sciences Circulating Tumor Cells Product Portfolio
  30. 6.5.5 Epic Sciences Recent Developments
  31. 6.6 Greiner Bio-one GmbH
  32. 6.6.1 Greiner Bio-one GmbH Company Information
  33. 6.6.2 Greiner Bio-one GmbH Business Overview
  34. 6.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio
  36. 6.6.5 Greiner Bio-one GmbH Recent Developments
  37. 6.7 Cynvenio
  38. 6.7.1 Cynvenio Company Information
  39. 6.7.2 Cynvenio Business Overview
  40. 6.7.3 Cynvenio Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Cynvenio Circulating Tumor Cells Product Portfolio
  42. 6.7.5 Cynvenio Recent Developments
  43. 6.8 SurExamBio-Tech
  44. 6.8.1 SurExamBio-Tech Company Information
  45. 6.8.2 SurExamBio-Tech Business Overview
  46. 6.8.3 SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 SurExamBio-Tech Circulating Tumor Cells Product Portfolio
  48. 6.8.5 SurExamBio-Tech Recent Developments
  49. 6.9 Fluxion Biosciences
  50. 6.9.1 Fluxion Biosciences Company Information
  51. 6.9.2 Fluxion Biosciences Business Overview
  52. 6.9.3 Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Fluxion Biosciences Circulating Tumor Cells Product Portfolio
  54. 6.9.5 Fluxion Biosciences Recent Developments
  55. 6.10 Ikonisys
  56. 6.10.1 Ikonisys Company Information
  57. 6.10.2 Ikonisys Business Overview
  58. 6.10.3 Ikonisys Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Ikonisys Circulating Tumor Cells Product Portfolio
  60. 6.10.5 Ikonisys Recent Developments
  61. 6.11 Hangzhou Watson Biotech
  62. 6.11.1 Hangzhou Watson Biotech Company Information
  63. 6.11.2 Hangzhou Watson Biotech Business Overview
  64. 6.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio
  66. 6.11.5 Hangzhou Watson Biotech Recent Developments
  67. 6.12 Biocept
  68. 6.12.1 Biocept Company Information
  69. 6.12.2 Biocept Business Overview
  70. 6.12.3 Biocept Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Biocept Circulating Tumor Cells Product Portfolio
  72. 6.12.5 Biocept Recent Developments
  73. 6.13 CytoTrack
  74. 6.13.1 CytoTrack Company Information
  75. 6.13.2 CytoTrack Business Overview
  76. 6.13.3 CytoTrack Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 CytoTrack Circulating Tumor Cells Product Portfolio
  78. 6.13.5 CytoTrack Recent Developments
  79. 6.14 Guangzhou Wondfo Biotech
  80. 6.14.1 Guangzhou Wondfo Biotech Company Information
  81. 6.14.2 Guangzhou Wondfo Biotech Business Overview
  82. 6.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio
  84. 6.14.5 Guangzhou Wondfo Biotech Recent Developments
  85. 6.15 Celsee
  86. 6.15.1 Celsee Company Information
  87. 6.15.2 Celsee Business Overview
  88. 6.15.3 Celsee Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Celsee Circulating Tumor Cells Product Portfolio
  90. 6.15.5 Celsee Recent Developments
  91. 6.16 Clearbridge Biomedics
  92. 6.16.1 Clearbridge Biomedics Company Information
  93. 6.16.2 Clearbridge Biomedics Business Overview
  94. 6.16.3 Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Clearbridge Biomedics Circulating Tumor Cells Product Portfolio
  96. 6.16.5 Clearbridge Biomedics Recent Developments
  97. 6.17 ANGLE plc
  98. 6.17.1 ANGLE plc Company Information
  99. 6.17.2 ANGLE plc Business Overview
  100. 6.17.3 ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 ANGLE plc Circulating Tumor Cells Product Portfolio
  102. 6.17.5 ANGLE plc Recent Developments
7 North America
  1. 7.1 North America Circulating Tumor Cells Market Size (2021-2032)
  2. 7.2 North America Circulating Tumor Cells Market Size by Type
  3. 7.2.1 North America Circulating Tumor Cells Market Size by Type (2021-2026)
  4. 7.2.2 North America Circulating Tumor Cells Market Size by Type (2027-2032)
  5. 7.2.3 North America Circulating Tumor Cells Market Share by Type (2021-2032)
  6. 7.3 North America Circulating Tumor Cells Market Size by Application
  7. 7.3.1 North America Circulating Tumor Cells Market Size by Application (2021-2026)
  8. 7.3.2 North America Circulating Tumor Cells Market Size by Application (2027-2032)
  9. 7.3.3 North America Circulating Tumor Cells Market Share by Application (2021-2032)
  10. 7.4 North America Circulating Tumor Cells Market Size by Country
  11. 7.4.1 North America Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Circulating Tumor Cells Market Size by Country (2021-2026)
  13. 7.4.3 North America Circulating Tumor Cells Market Size by Country (2027-2032)
  14. 7.4.4 North America Circulating Tumor Cells Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Circulating Tumor Cells Market Size (2021-2032)
  2. 8.2 Europe Circulating Tumor Cells Market Size by Type
  3. 8.2.1 Europe Circulating Tumor Cells Market Size by Type (2021-2026)
  4. 8.2.2 Europe Circulating Tumor Cells Market Size by Type (2027-2032)
  5. 8.2.3 Europe Circulating Tumor Cells Market Share by Type (2021-2032)
  6. 8.3 Europe Circulating Tumor Cells Market Size by Application
  7. 8.3.1 Europe Circulating Tumor Cells Market Size by Application (2021-2026)
  8. 8.3.2 Europe Circulating Tumor Cells Market Size by Application (2027-2032)
  9. 8.3.3 Europe Circulating Tumor Cells Market Share by Application (2021-2032)
  10. 8.4 Europe Circulating Tumor Cells Market Size by Country
  11. 8.4.1 Europe Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Circulating Tumor Cells Market Size by Country (2021-2026)
  13. 8.4.3 Europe Circulating Tumor Cells Market Size by Country (2027-2032)
  14. 8.4.4 Europe Circulating Tumor Cells Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Circulating Tumor Cells Market Size (2021-2032)
  2. 9.2 China Circulating Tumor Cells Market Size by Type
  3. 9.2.1 China Circulating Tumor Cells Market Size by Type (2021-2026)
  4. 9.2.2 China Circulating Tumor Cells Market Size by Type (2027-2032)
  5. 9.2.3 China Circulating Tumor Cells Market Share by Type (2021-2032)
  6. 9.3 China Circulating Tumor Cells Market Size by Application
  7. 9.3.1 China Circulating Tumor Cells Market Size by Application (2021-2026)
  8. 9.3.2 China Circulating Tumor Cells Market Size by Application (2027-2032)
  9. 9.3.3 China Circulating Tumor Cells Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Circulating Tumor Cells Market Size (2021-2032)
  2. 10.2 Asia Circulating Tumor Cells Market Size by Type
  3. 10.2.1 Asia Circulating Tumor Cells Market Size by Type (2021-2026)
  4. 10.2.2 Asia Circulating Tumor Cells Market Size by Type (2027-2032)
  5. 10.2.3 Asia Circulating Tumor Cells Market Share by Type (2021-2032)
  6. 10.3 Asia Circulating Tumor Cells Market Size by Application
  7. 10.3.1 Asia Circulating Tumor Cells Market Size by Application (2021-2026)
  8. 10.3.2 Asia Circulating Tumor Cells Market Size by Application (2027-2032)
  9. 10.3.3 Asia Circulating Tumor Cells Market Share by Application (2021-2032)
  10. 10.4 Asia Circulating Tumor Cells Market Size by Country
  11. 10.4.1 Asia Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Circulating Tumor Cells Market Size by Country (2021-2026)
  13. 10.4.3 Asia Circulating Tumor Cells Market Size by Country (2027-2032)
  14. 10.4.4 Asia Circulating Tumor Cells Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Circulating Tumor Cells Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Circulating Tumor Cells Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Circulating Tumor Cells Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Circulating Tumor Cells Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Circulating Tumor Cells Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Circulating Tumor Cells Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Circulating Tumor Cells Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Circulating Tumor Cells Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Circulating Tumor Cells Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Circulating Tumor Cells Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Circulating Tumor Cells Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Circulating Tumor Cells Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst